The second was a prospective, phase II study evaluating the therapeutic value of liposomal anthracyclines in HER2 positive breast cancer with dual anti-HER2 therapy (trastuzumab + pertuzumab) in evaluating cardiac safety given the possibility of increased cardiotoxicity with anthracyclines and trastuzumab [36]. Here, ERBB2 is linked to breast carcinoma.